Literature DB >> 1335337

Use of selective antagonists to dissociate the central cardiovascular and behavioural effects of tachykinins on NK1 and NK2 receptors in the rat.

C Tschöpe1, P Picard, J Culman, A Prat, K Itoi, D Regoli, T Unger, R Couture.   

Abstract

1. The effects of intracerebroventricular (i.c.v.) pretreatment with selective NK1 ((+/-)-CP 96,345), NK2a (MEN 10,207; MEN 10,376) and NK2b (R 396) tachykinin receptor antagonists on the cardiovascular and behavioural responses to i.c.v. substance P (SP) and neurokinin A (NKA) were studied in conscious rats. 2. SP and NKA (25 pmol) induced mean arterial blood pressure and heart rate increases of the same magnitude and duration. The cardiovascular responses to both peptides were accompanied by excessive face washing, sniffing, grooming and wet dog shakes. 3. The cardiovascular responses to SP but not to NKA were attenuated by pretreatment with a NK1 receptor antagonist, (+/-)-CP 96,345. Of the behavioural responses, only face washing was significantly inhibited. 4. The cardiovascular and behavioural effects of NKA but not of SP were significantly attenuated by pretreatment with the selective NK2b receptor antagonist, R 396. 5. The selective NK2a receptor antagonists, MEN 10,207 and MEN 10,376, did not affect the cardiovascular and behavioural responses to either SP or NKA. 6. These results suggest, firstly, that the cardiovascular and behavioural effects of i.c.v. SP are mediated by NK1 receptors; secondly, that NKA injected i.c.v. does not interact with NK1 receptors but with another type of tachykinin receptor which may belong to the NK2b subclass. These findings provide pharmacological evidence for the existence of functionally active NK2 receptors in the rat brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335337      PMCID: PMC1907752          DOI: 10.1111/j.1476-5381.1992.tb14518.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Species differences in affinities of non-peptide antagonists for substance P receptors.

Authors:  B D Gitter; D C Waters; R F Bruns; N R Mason; J A Nixon; J J Howbert
Journal:  Eur J Pharmacol       Date:  1991-05-17       Impact factor: 4.432

Review 2.  Selective neurokinin receptor radioligands.

Authors:  R Quirion; T V Dam; S Guard
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

3.  Behavioural effects of tachykinins and related peptides.

Authors:  P J Elliott; S D Iversen
Journal:  Brain Res       Date:  1986-08-27       Impact factor: 3.252

4.  Evidence for the existence of three classes of neurokinin receptors in brain. Differential ontogeny of neurokinin-1, neurokinin-2 and neurokinin-3 binding sites in rat cerebral cortex.

Authors:  T V Dam; E Escher; R Quirion
Journal:  Brain Res       Date:  1988-06-21       Impact factor: 3.252

5.  gamma-Preprotachykinin-(72-92)-peptide amide: an endogenous preprotachykinin I gene-derived peptide that preferentially binds to neurokinin-2 receptors.

Authors:  T V Dam; Y Takeda; J E Krause; E Escher; R Quirion
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  Sympathoadrenal mechanisms underlying cardiovascular responses to intrathecal substance P in conscious rats.

Authors:  H Hasséssian; R Couture; J de Champlain
Journal:  J Cardiovasc Pharmacol       Date:  1990-05       Impact factor: 3.105

7.  In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376.

Authors:  C A Maggi; S Giuliani; L Ballati; A Lecci; S Manzini; R Patacchini; A R Renzetti; P Rovero; L Quartara; A Giachetti
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

8.  Competitive antagonists discriminate between NK2 tachykinin receptor subtypes.

Authors:  C A Maggi; R Patacchini; S Giuliani; P Rovero; S Dion; D Regoli; A Giachetti; A Meli
Journal:  Br J Pharmacol       Date:  1990-07       Impact factor: 8.739

9.  Role of central tachykinin peptides in cardiovascular regulation in rats.

Authors:  Y Takano; A Nagashima; T Hagio; K Tateishi; H Kamiya
Journal:  Brain Res       Date:  1990-10-01       Impact factor: 3.252

10.  Characterization of a tachykinin peptide NK2 receptor transfected into murine fibroblast B82 cells.

Authors:  P L van Giersbergen; S A Shatzer; A K Henderson; J Lai; S Nakanishi; H I Yamamura; S H Buck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

View more
  12 in total

1.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

2.  Behavioral effects of local microinfusion of pituitary adenylate cyclase activating polypeptide (PACAP) into the paraventricular nucleus of the hypothalamus (PVN).

Authors:  Seth D Norrholm; Mahasweta Das; Gábor Légrádi
Journal:  Regul Pept       Date:  2005-05-15

Review 3.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

4.  Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists.

Authors:  P Picard; R Couture
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

5.  Respiratory action of capsaicin microinjected into the nucleus of the solitary tract: involvement of vanilloid and tachykinin receptors.

Authors:  S B Mazzone; D P Geraghty
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

6.  Pituitary adenylate cyclase-activating polypeptide (PACAP) mimics neuroendocrine and behavioral manifestations of stress: Evidence for PKA-mediated expression of the corticotropin-releasing hormone (CRH) gene.

Authors:  Anika Agarwal; Lisa M Halvorson; Gabor Legradi
Journal:  Brain Res Mol Brain Res       Date:  2005-07-29

7.  Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.

Authors:  E Cellier; L Barbot; S Iyengar; R Couture
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

8.  Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.

Authors:  J Culman; B Wiegand; H Spitznagel; S Klee; T Unger
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

9.  Comparative behavioural profile of centrally administered tachykinin NK1, NK2 and NK3 receptor agonists in the guinea-pig.

Authors:  O Piot; J Betschart; I Grall; S Ravard; C Garret; J C Blanchard
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Cardiovascular and behavioural effects of centrally administered tachykinins in the rat: characterization of receptors with selective antagonists.

Authors:  P Picard; D Regoli; R Couture
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.